Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
92 Results for "
ENPP
" in MedChemExpress (MCE) Product Catalog:
Products (92)
92 Results for "ENPP" in MCE Product Catalog:
Cat. No.: HY-153334
CAS No.: 2756218-99-0
Target:
Research Areas:
Enpp-1-IN-15 (Compound 88a) is an Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp-1) Inhibitor, with a Ki value of 0.00586 nM .
Cat. No.: HY-126233
CAS No.: 1689554-51-5
Target:
Research Areas:
PAT-347 is an inhibitor of autotaxin (ATX, ENPP-2) . PAT-347 binds only to the hydrophobic channel of ATX, without occupying its hydrophobic pocket and catalytic site . PAT-347 blocks the binding of lysophosphatidylcholine (LPC) to the catalytic site of ATX .
Cat. No.: HY-P991706
CAS No.: 3029433-56-2
Target:
Research Areas:
Cat. No.: HY-176828
Target:
Research Areas:
Enpp-1-IN-28 is a ENPP1 inhibitor at the molecular and cellular levels, with IC50 values of 0.188 µM and 0.732 µM, respectively. Enpp-1-IN-28 upgrades the expression levels of IFN-β in vivo by preventing the ENPP1 from hydrolyzing the cGAMP to stimulate a more potent innate immune response. Enpp-1-IN-28 can be used for the study of metastatic breast cancer .
Cat. No.: HY-176874
CAS No.: 2944114-41-2
Target:
Research Areas:
Enpp-1-IN-29 (Compound 1) is a highly selective ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor (IC50=0.05 nM). Enpp-1-IN-29 is promising for research of ENPP1-overexpressing cancers (e.g., breast cancer, head/neck cancer, metastatic chromosome-unstable tumors) and immune-related diseases (e.g., autoimmune disorders, tumor immune evasion) .
Research Areas:
Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-1 induces Apoptosis .
Cat. No.: HY-P991677
CAS No.: 2770242-54-9
Synonyms: INZ-701
Target:
Research Areas:
Cat. No.: HY-172527
Target:
Research Areas:
CD73-IN-20 (Compound 5c) is an e5′NT (CD73) inhibitor (IC50: 0.37 μM). CD73-IN-20 also inhibits other ectonucleotidases, with IC50s of 1.12 μM (h-ENPP1), 1.37 μM (h-ENPP3), 1.66 μM (r-e5′NT), 1.48 μM (h-TNAP), respectively. CD73-IN-20 can be used for cancer research .
Cat. No.: HY-162912
CAS No.: 2954111-03-4
Target:
Research Areas:
Enpp-1-IN-23 (compound 27) is an Enpp-1 inhibitor, with IC50 of 1.2 nM. Enpp-1-IN-23 can be used in cancer research .
Cat. No.: HY-175047
CAS No.: 2848714-91-8
Target:
Research Areas:
Enpp-1-IN-26 (Compound 4e) is an ENPP1 inhibitor with an IC50 of 0.188 μM. Enpp-1-IN-26 enhances IFN-β expression in vivo by preventing ENPP1 from hydrolyzing cGAMP. Enpp-1-IN-26 can be used in the research of metastatic breast cancer .
Cat. No.: HY-147998
CAS No.: 2417022-19-4
Target:
Research Areas:
Enpp-1-IN-13 (Compound 1a) is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) inhibitor with IC50 values of 1.29 μM and 20.2 μM against ENPP1 and ENPP3, respectively. Enpp-1-IN-13 shows anticancer activity .
Cat. No.: HY-145062
CAS No.: 2376600-89-2
Target:
Research Areas:
Enpp-1-IN-4 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). Enpp-1-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2019177971A1, compound 1) .
Cat. No.: HY-168491
CAS No.: 3067908-20-4
Target:
Research Areas:
Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy .
Cat. No.: HY-145064
CAS No.: 2718971-29-8
Target:
Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-6 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Cat. No.: HY-145065
Target:
Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-7 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Cat. No.: HY-145069
CAS No.: 2718971-08-3
Target:
Research Areas:
Enpp-1-IN-8 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-8 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Cat. No.: HY-145070
CAS No.: 2718970-70-6
Target:
Enpp-1-IN-9 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-9 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Cat. No.: HY-172528
Target:
Research Areas:
Enpp-1/3-IN-1 (Compound 5j) is an ENPP1/ENPP3 inhibitor, with IC50s of 0.59 μM (h-ENPP1) and 0.62 μM (h-ENPP3) respectively. Enpp-1/3-IN-1 also inhibits e5′NT (CD73) and TNAP with IC50s of 0.89 μM (h-e5′NT), 5.12 μM (r-e5′NT) and 1.68 μM (h-TNAP), respectively. Enpp-1/3-IN-1 can be used for cancer research .
Cat. No.: HY-162911
CAS No.: 2954111-09-0
Target:
Research Areas:
Enpp-1-IN-22 is an orally bioavailable prodrug of the potent ENPP1 inhibitor paraformaldehyde with antitumor activity .
Target:
Research Areas:
Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-5 has the potential for the research of cancer and infectious diseases (extracted from patent WO2019046778A1/WO2021203772A1, compound 1) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
